MARKET

CMMB

CMMB

Chemomab Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.13
-0.26
-4.82%
Closed 16:00 01/24 EST
OPEN
5.24
PREV CLOSE
5.39
HIGH
5.28
LOW
4.750
VOLUME
73.82K
TURNOVER
--
52 WEEK HIGH
168.80
52 WEEK LOW
4.750
MARKET CAP
58.47M
P/E (TTM)
-0.1697
1D
5D
1M
3M
1Y
5Y
ISO, CMMB and CTMX among technology movers
Gainers: Reliance Global Group (NASDAQ:RELI) +89%. Biofrontera  (NASDAQ:BFRI) +49%. IsoPlexis Corporation (NASDAQ:ISO) +37%. Chemomab Therapeutics  (NASDAQ:CMMB) +29%. iSpecimen  (NASDAQ:ISPC) +28%. Aldeyra Therapeutics (NASDAQ:ALDX) -51%. DBV Technologies...
Seekingalpha · 12/21/2021 20:44
Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that senior manag...
PR Newswire · 12/20/2021 13:00
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Benzinga · 12/16/2021 23:03
BRIEF-Chemomab Therapeutics Announces Expected Appointment Of Dale R. Pfost As Chairman
reuters.com · 12/16/2021 21:12
Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that, as planned a...
PR Newswire · 12/16/2021 21:05
Aegis Capital Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $30
Aegis Capital analyst Nathan Weinstein initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and announces Price Target of $30.
Benzinga · 12/07/2021 14:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 12/06/2021 13:06
Chemomab Therapeutics chief medical officer resigns
Chemomab Therapeutics (NASDAQ:CNNB) announced that David M. Weiner has been appointed as the company’s Interim Chief Medical Officer, effective immediately. The appointment made on a part-time basis follows the resignation
Seekingalpha · 12/03/2021 13:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CMMB. Analyze the recent business situations of Chemomab Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CMMB stock price target is 35.00 with a high estimate of 45.00 and a low estimate of 30.00.
High45.00
Average35.00
Low30.00
Current 5.13
EPS
Actual
Estimate
-3.70-2.77-1.85-0.92
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 20
Institutional Holdings: 3.55M
% Owned: 31.13%
Shares Outstanding: 11.40M
TypeInstitutionsShares
Increased
1
1.61K
New
7
294.73K
Decreased
4
19.70K
Sold Out
4
120.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Squinto
Chief Executive Officer/Chief Scientific Officer/Director
Adi Mor
Chief Financial Officer/Chief Operating Officer/Executive Vice President
Donald Marvin
Other
Aaron Aharon
Independent Director
Neil Cohen
Independent Director
Nissim Darvish
Independent Director
Joel Maryles
Independent Director
Alan Moses
Independent Director
Claude Nicaise
No Data
  • All
  • Financials
  • Insiders
More
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Webull offers kinds of Chemomab Therapeutics Ltd - ADR stock information, including NASDAQ:CMMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMMB stock methods without spending real money on the virtual paper trading platform.